Vestronidase alfa (MEPSEVII®)

Assessment Status Rapid review complete
Drug Vestronidase alfa
Indication For the treatment of non-neurological manifestations of MPS VII.
Assessment Process
Rapid review commissioned 09/04/2019
Rapid review completed 22/05/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.